Gene Editing

Bill Gates Gets Excited About Future Of Tech That Has 'Revolutionized Health' Over Past Decade

Beam Therapeutics Touts Encouraging Preclinical Data From Gene Editing Approach For Hepatitis B Infection

FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials

Beam Therapeutics Touts Encouraging Preclinical Data From Gene Editing Approach For Hepatitis B Infection

FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials

Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents

Intellia Shares Updated Data On Gene Editing Durability In Rare Disease

Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents

|

Intellia Shares Updated Data On Gene Editing Durability In Rare Disease

|

Sarepta Bets On GenEdit's Nanoparticles' In $57M Gene Editing Partnership

|

Pfizer, Beam Ink Multi-Target Research Collaboration For In Vivo Base Editing Programs

|

Gene Editing Recent News

Jennifer Doudna Spinout Mammoth Inks $700M CRISPR Deal With Vertex

|

Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology

|

Intellia To Test Second CRISPR Therapeutic In Hereditary Angioedema Patients

|

Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate

|

Wave Life Sciences Shows Durable ADAR-Editing In Multiple Tissues In Animal Studies

|

Beam Therapeutics' Base Editors Show Encouraging Preclinical Action In HBV Infection

|

Beam Therapeutics' Formulated LNP Show Tolerance, Early Storage Stability In Animal Studies

|

Shape Therapeutics, Roche Form $3B RNA Editing Collaboration

|

Vertex Inks Potential $1.2B Gene-Editing Pact With Arbor Biotechnologies

|

Editas Medicine Unveils Preclinical Data From New Gene Editing Technology

|

Graphite Bio's Approach To Gene Editing Has BofA Securities and Morgan Stanley Bullish

A differentiated approach to gene editing has ushered a bullish sentiment from BofA Securities and Morgan Stanley on Graphite Bio, Inc.

|

Heart Disease Company Tenaya Therapeutics Files For $100M US IPO

|

WHO Issues Framework For Governance For Gene Editing Technologies

|

Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders

|

In Future CRISPR Gene Editing To Treat Diseases, Says Intellia Co-Founder: CNBC

Gene-editing technology CRISPR reached a significant milestone this week, completing its first systemic delivery as a medicine to the human body.

|

Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate

|

Qiagen Launches CRISPR-Specific Products For Gene-Editing Experiments

|

Precision BioSciences Shares Move Higher As ARCUS Platform Shows Promising Gene Editing Approach For Transthyretin Amyloidosis

|

Precision Bio's ARCUS Gene Editing Platform Is Safe, Durable; Long-Term Animal Study Shows

|

Cellectis, Cytovia Therapeutics Ink Gene-Edited Therapy Pact For Oncology Indications

|

Chinese 'Gene-Editing' Scientist Gets 3 Years In Prison

|

Crispr's Gene-Editing Therapy Found Effective In Treating Blood Disorders In Early-Stage Study

|

Baird: Preclinical Data Inspires 'Early Optimism' In Lead Intellia Therapeutics Asset

|